Multifunctional Substrate for Early Detection of Oxidative Stress Susceptibility and Application to Parkinson's Disease
This study is currently recruiting participants.
Verified December 2005 by Hillel Yaffe Medical Center
Sponsor:
Hillel Yaffe Medical Center
Collaborator:
Technion, Israel Institute of Technology
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00271141
First received: December 29, 2005
Last updated: NA
Last verified: December 2005
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The proposed work is based on the detection of a novel molecule for sensitivity to oxidative stress in humans in venous blood
| Condition |
|---|
|
Parkinson's Disease Oxidative Stress |
| Study Type: | Observational |
| Study Design: | Additional Descriptors: Convenience Sample Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Retrospective |
| Official Title: | Multifunctional Substrate for Early Detection of Oxidative Stress Susceptibility and Application to Parkinson's Disease |
Resource links provided by NLM:
Further study details as provided by Hillel Yaffe Medical Center:
| Estimated Enrollment: | 500 |
| Study Start Date: | May 2005 |
| Estimated Study Completion Date: | December 2015 |
Since alterations in mitochondrial functions in platelets and lymphocytes have been detected in Parkinson's disease we plan to monitor the metabolism a a new molecule (LTG) in the blood samples of Parkinson's disease patients and compare them to controls. We shall use 10 cc of venous blood and analyze serum, white blood cells and platelets. We shall not extract nor use DNA.The main purpose is to develop a marker for Parkinson's disease in venous blood.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
Parkinson's disease Healthy control -
Exclusion Criteria:
None -
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00271141
Contacts
| Contact: Rivka Inzelberg, MD | +972-4-6304607 | inzelberg@hy.health.gov.il |
Locations
| Israel | |
| Hillel Yaffe Medical Center | Recruiting |
| Hadera, Israel | |
| Principal Investigator: Rivka Inzelberg, MD | |
Sponsors and Collaborators
Hillel Yaffe Medical Center
Technion, Israel Institute of Technology
Investigators
| Principal Investigator: | Rivka Inzelberg, MD | Hillel Yaffe Medical Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00271141 History of Changes |
| Other Study ID Numbers: | hy11/2005 |
| Study First Received: | December 29, 2005 |
| Last Updated: | December 29, 2005 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Hillel Yaffe Medical Center:
|
Parkinson's disease Oxidative stress Marker |
Additional relevant MeSH terms:
|
Disease Susceptibility Genetic Predisposition to Disease Parkinson Disease Disease Attributes Pathologic Processes Parkinsonian Disorders |
Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |
ClinicalTrials.gov processed this record on May 23, 2013